<DOC>
	<DOCNO>NCT00165620</DOCNO>
	<brief_summary>To establish optimum injection rate E7337 ( Iomeron 350 ) dynamic CT patient hepatic lesions.The primary endpoint efficacy contrast enhancement effect early arterial phase , primary safety endpoint warm sensation vascular pain .</brief_summary>
	<brief_title>A Randomized , Open , Parallel , Optimal Injection Rate-Finding Study E7337 Dynamic CT Liver Patients With Liver Disease</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteira : Patients schedule dynamic CT scan liver least one hepatic lesion confirm diagnostic imaging ( ultrasonography , etc . ) 1 35 day start study treatment . Patients 20 year old time obtain informed consent . Exclusion Criteria Items may affect safety evaluation E7337 1 . Patients undergone schedule undergo examination use another contrast agent 7 day administration E7337 time followup examination Day 8 administration . 2 . Patients followups seem difficult conduct time examination Day 8 ( i.e . may fail evaluate delayed adverse drug reaction ) . 3 . Patients undergone schedule undergo surgical treatment therapy percutaneous ethanol injection therapy , percutaneous microwave coagulation therapy , radiofrequency ablation , transcatheter arterial embolization , etc. , time diagnostic image abdominal ultrasonography perform followup examination conduct Day 8 administration . 4 . Patients continuously need take analgesic morning administration E7337 completion CT examination . 5 . Patients currently participate another clinical study . 6 . Patients participate another clinical study within 3 month prior provide inform consent study . 7 . Patients weigh less 55 kg ( body weight time obtain informed consent ) . General concern relate safety subject . 1 . Patients acute stage clinically unstable symptom , lifethreatening condition ( expect emergency treatment required time registration end followup period , patient expect survive 3 month follow administration E7337 , etc . ) 2 . Patients history hypersensitivity iodine iodinate contrast agent . 3 . Patients serious thyroid disease ( goiter , hyperthyroidism , etc . ) 4 . Patients serious cardiopathy ( NYHA functional class IV heart failure describe Appendix 5 , shock , cyanosis , peripheral circulatory insufficiency , ventricular tachycardia , ventricular fibrillation , complete atrioventricular block ) 5 . Patients serious hepatopathy ( symptom liver failure [ fulminant hepatitis ] disturbance consciousness correspond grade 3 Criteria Grading Adverse Drug Reactions Medicinal Products Appendix 5 ) . 6 . Patients moderate serious nephropathy ( acute chronic renal failure , hydronephrosis , nephrotic syndrome , uremia serum creatinine level 2.0 mg/dL , correspond grade 2 Criteria Grading Adverse Drug Reactions Medicinal Products Appendix 5 ) . 7 . Patients bronchial asthma 8 . Patients acute pancreatitis 9 . Patients macroglobulinemia 10 . Patients multiple myeloma 11 . Patients tetany 12 . Patients pheochromocytoma suspect pheochromocytoma 13 . Women pregnant , childbearing potential , lactate 14 . Patients history hypersensitivity drug ( ) 15 . Patients hypertension medication 16 . Patients diabetes medication 17 . Patients serious illness myasthenia 18 . Patients judge ineligible study entry investigator subinvestigator reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>